Rakuten Investment Management Inc. Raises Holdings in AbbVie Inc. $ABBV

Rakuten Investment Management Inc. increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 10.2% during the 2nd quarter, Holdings Channel reports. The fund owned 289,091 shares of the company’s stock after purchasing an additional 26,793 shares during the quarter. AbbVie makes up about 0.2% of Rakuten Investment Management Inc.’s investment portfolio, making the stock its 28th largest position. Rakuten Investment Management Inc.’s holdings in AbbVie were worth $73,519,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Norges Bank acquired a new position in AbbVie in the fourth quarter valued at approximately $5,865,055,000. Corient Private Wealth LP acquired a new stake in shares of AbbVie during the 2nd quarter worth approximately $559,736,000. Legal & General Group Plc purchased a new position in shares of AbbVie during the 2nd quarter valued at approximately $2,905,952,000. Wellington Management Group LLP increased its holdings in shares of AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares in the last quarter. Finally, Capital World Investors lifted its stake in shares of AbbVie by 106.3% in the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock valued at $2,986,777,000 after purchasing an additional 6,736,161 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $256.27 on Monday. The firm has a market cap of $452.78 billion, a PE ratio of 72.39, a PEG ratio of 1.16 and a beta of 0.29. The firm has a fifty day moving average of $254.66 and a 200 day moving average of $230.05. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period last year, the company posted $2.97 EPS. AbbVie’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio is 195.48%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial
• Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics
• Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case.
• Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics
• Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth.

Insider Buying and Selling

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ABBV. Canaccord Genuity Group increased their price target on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. HSBC reiterated a “buy” rating and issued a $300.00 price objective on shares of AbbVie in a research report on Monday, July 6th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Barclays raised their target price on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Finally, Weiss Ratings raised AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $275.95.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.